These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 28146267

  • 1. Low T3 syndrome is a strong prognostic predictor in diffuse large B cell lymphoma.
    Gao R, Liang JH, Wang L, Zhu HY, Wu W, Wu JZ, Xia Y, Cao L, Fan L, Yang T, Li JY, Xu W.
    Br J Haematol; 2017 Apr; 177(1):95-105. PubMed ID: 28146267
    [Abstract] [Full Text] [Related]

  • 2. Low T3 syndrome as a predictor of poor prognosis in chronic lymphocytic leukemia.
    Gao R, Chen RZ, Xia Y, Liang JH, Wang L, Zhu HY, Zhu Wu J, Fan L, Li JY, Yang T, Xu W.
    Int J Cancer; 2018 Aug 01; 143(3):466-477. PubMed ID: 29457831
    [Abstract] [Full Text] [Related]

  • 3. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
    El-Galaly TC, Villa D, Alzahrani M, Hansen JW, Sehn LH, Wilson D, de Nully Brown P, Loft A, Iyer V, Johnsen HE, Savage KJ, Connors JM, Hutchings M.
    Am J Hematol; 2015 Nov 01; 90(11):1041-6. PubMed ID: 26260224
    [Abstract] [Full Text] [Related]

  • 4. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
    Adams HJ, de Klerk JM, Fijnheer R, Heggelman BG, Dubois SV, Nievelstein RA, Kwee TC.
    Clin Lymphoma Myeloma Leuk; 2015 Nov 01; 15(11):671-9. PubMed ID: 26361646
    [Abstract] [Full Text] [Related]

  • 5. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
    Troppan KT, Melchardt T, Deutsch A, Schlick K, Stojakovic T, Bullock MD, Reitz D, Beham-Schmid C, Weiss L, Neureiter D, Wenzl K, Greil R, Neumeister P, Egle A, Pichler M.
    Eur J Haematol; 2015 Dec 01; 95(6):538-44. PubMed ID: 25677782
    [Abstract] [Full Text] [Related]

  • 6. Visceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP.
    Shin DY, Kim A, Byun BH, Moon H, Kim S, Ko YJ, Kim MJ, Lee HR, Kang HJ, Na II, Park S, Lee SS, Yang SH.
    Ann Hematol; 2016 Feb 01; 95(3):409-16. PubMed ID: 26658607
    [Abstract] [Full Text] [Related]

  • 7. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor.
    Bairey O, Shacham-Abulafia A, Shpilberg O, Gurion R.
    Hematol Oncol; 2016 Dec 01; 34(4):184-192. PubMed ID: 26052918
    [Abstract] [Full Text] [Related]

  • 8. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C, Li W, Liu C, He H, Bai O.
    Blood Cells Mol Dis; 2016 Mar 01; 57():42-9. PubMed ID: 26852654
    [Abstract] [Full Text] [Related]

  • 9. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
    Huang YC, Liu CY, Lu HJ, Liu HT, Hung MH, Hong YC, Hsiao LT, Gau JP, Liu JH, Hsu HC, Chiou TJ, Chen PM, Tzeng CH, Yu YB.
    Ann Hematol; 2013 Nov 01; 92(11):1513-20. PubMed ID: 23775580
    [Abstract] [Full Text] [Related]

  • 10. Low T3 syndrome as a predictor of poor outcomes in patients with follicular lymphoma.
    Xue LG, Shen HR, Gao R, Du KX, Xing TY, Wang WT, Wang L, Li JY, Liang JH, Xu W.
    Ann Hematol; 2023 Apr 01; 102(4):851-862. PubMed ID: 36735075
    [Abstract] [Full Text] [Related]

  • 11. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, Connors JM, Gascoyne RD.
    J Clin Oncol; 2011 Apr 10; 29(11):1452-7. PubMed ID: 21383296
    [Abstract] [Full Text] [Related]

  • 12. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Wang Y, Li YJ, Jiang WQ, Rao HL, Huang JJ, Xia Y, Bi X, Sun P, Huang HQ, Lin TY, Guan ZZ, Li ZM.
    Ann Hematol; 2015 Nov 10; 94(11):1865-73. PubMed ID: 26327569
    [Abstract] [Full Text] [Related]

  • 13. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β2 -microglobulin yields a more accurate GELTAMO-IPI.
    Montalbán C, Díaz-López A, Dlouhy I, Rovira J, Lopez-Guillermo A, Alonso S, Martín A, Sancho JM, García O, Sánchez JM, Rodríguez M, Novelli S, Salar A, Gutiérrez A, Rodríguez-Salazar MJ, Bastos M, Domínguez JF, Fernández R, Gonzalez de Villambrosia S, Queizan JA, Córdoba R, de Oña R, López-Hernandez A, Freue JM, Garrote H, López L, Martin-Moreno AM, Rodriguez J, Abraira V, García JF, GELTAMO-IPI Project InvestigatorsDepartment of Translational Research, MD Anderson Cancer Centre, Madrid, Spain.Department of Pathology, MD Anderson Cancer Centre, Madrid, Spain..
    Br J Haematol; 2017 Mar 10; 176(6):918-928. PubMed ID: 28106247
    [Abstract] [Full Text] [Related]

  • 14. Low serum cholesterol levels predict inferior prognosis and improve NCCN-IPI scoring in diffuse large B cell lymphoma.
    Gao R, Liang JH, Wang L, Zhu HY, Wu W, Cao L, Fan L, Li JY, Yang T, Xu W.
    Int J Cancer; 2018 Oct 15; 143(8):1884-1895. PubMed ID: 29744861
    [Abstract] [Full Text] [Related]

  • 15. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, Connors JM, Gratzinger D, Rosado M, Zhao S, Pohlman B, Wongchaowart N, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE, Levy R, Gascoyne RD, Lossos IS.
    J Clin Oncol; 2008 Jan 20; 26(3):447-54. PubMed ID: 18086797
    [Abstract] [Full Text] [Related]

  • 16. [Analysis of survival and prognosis in 409 newly diagnosed patients with diffuse large B-cell lymphoma].
    Wen J, Zhou J, Liu Z, Liu T, Xu C.
    Zhonghua Xue Ye Xue Za Zhi; 2014 Apr 20; 35(4):318-24. PubMed ID: 24759020
    [Abstract] [Full Text] [Related]

  • 17. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ, de Klerk JM, Fijnheer R, Heggelman BG, Dubois SV, Nievelstein RA, Kwee TC.
    Eur J Haematol; 2015 Jun 20; 94(6):532-9. PubMed ID: 25311082
    [Abstract] [Full Text] [Related]

  • 18. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, Morishima Y.
    Eur J Haematol; 2008 Dec 20; 81(6):448-53. PubMed ID: 18691256
    [Abstract] [Full Text] [Related]

  • 19. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma.
    Kim TM, Paeng JC, Chun IK, Keam B, Jeon YK, Lee SH, Kim DW, Lee DS, Kim CW, Chung JK, Kim IH, Heo DS.
    Cancer; 2013 Mar 15; 119(6):1195-202. PubMed ID: 23212736
    [Abstract] [Full Text] [Related]

  • 20. [Comparison of Different Staging Systems and Prognostic Analysis in 68 Cases of Primary Intestinal Diffuse Large B Cell Lymphoma].
    Wang X, Wang CY, Xu W, Yang HL, Zhao HF, Wang XF, Wang YF, Yu Y, Zhang YZ.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb 15; 27(1):52-60. PubMed ID: 30738447
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.